Wendianne Wilson
Optometrist · Urbandale, IANPI 1679569495
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,070 of the $14,330 with a category attached, or 63.3%. 23 manufacturers reported payments, led by Alcon at 32.7% of the total. Reporting peaked in 2022 at $3,869 and has fallen 65.3% since, to $1,343 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Johnson & Johnson Vision Care, Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Bausch & Lomb Americas Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$664
- Coopervision Inc.$624
- plus $2K from 17 others
Across 4 payments — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tarsus Pharmaceuticals, Inc.$1K
What the payments were for
- Consulting fees$4703%
- Travel & lodging$4,77033%
- Food & beverage$9,07063%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 99 | $4,683 |
| Johnson & Johnson Vision Care, Inc. | 67 | $2,875 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $1,874 |
| Bausch & Lomb Americas Inc. | 41 | $1,170 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $664 |
| Coopervision Inc. | 26 | $624 |
| Tarsus Pharmaceuticals, Inc. | 20 | $493 |
| Biotissue Holdings Inc. | 9 | $370 |
| Amgen | 3 | $355 |
| Oyster Point Pharma, Inc. | 13 | $335 |
| Kala Pharmaceuticals, Inc. | 2 | $143 |
| AbbVie | 8 | $142 |
| Shire North American Group Inc | 2 | $134 |
| LKC Technologies, Inc. | 2 | $126 |
| Novartis | 5 | $74 |
| Sun Pharmaceutical Industries Inc. | 4 | $66 |
| Genentech USA, Inc. | 1 | $59 |
| Alcon Research LLC | 1 | $42 |
| ABB Con-cise Optical Group LLC | 2 | $28 |
| Astellas Pharma US Inc | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$1,769
- BIOTRUE$1,305
- ULTRA$1,305
- AIR OPTIX$1,249
- DAILIES TOTAL1 Multifocal$1,249
- Dailies Aqua Comfort Plus$1,249
- DAILIES$543
- DAILIES TOTAL1$469
- Precision 1$364
- TEPEZZA$355
- TOTAL30$349
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$275
- XIIDRA$250
- TRYPTYR$245
- XDEMVY$242
- TYRVAYA$127
- MIEBO$125
- EYSUVIS$124
- INVELTYS$124
- Rocklatan$124
How this compares
$14,330 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $55,063 |
| XdemvyLotilaner | 21 | $39,803 |
| XiidraLifitegrast | 25 | $35,503 |
| MieboPerfluorohexyloctane/Pf | 15 | $17,251 |
| CequaCyclosporine | 23 | $15,565 |
| TyrvayaVarenicline Tartrate | 12 | $7,854 |
| Prednisolone Acetate | 40 | $1,904 |
| Latanoprost | 34 | $314 |
| Brimonidine Tartrate | 12 | $198 |
| Timolol Maleate | 23 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $142 | $55,06339 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,170 | $52,75440 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $493 | $39,80321 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $66 | $15,56523 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $335 | $7,85412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 optometrist providers in Iowa.
Other optometrist in Urbandale
- Melissa BillingsUrbandale$3K
- Sara ButterworthCoralville$191K
- Ethan HuismanWaukee$111K
- Kelsi SawatzkyWest Des Moines$26K
- Heidi BellClive$19K
- Jennifer DenhartogClive$16K
- Daniel KoenigAmes$11K
- Lexie FranzeenWest Des Moines$7K
- Mallori PhillipsGrimes$7K
- Gabrielle MageeWaukee$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.